<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55184">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01710332</url>
  </required_header>
  <id_info>
    <org_study_id>CSRII</org_study_id>
    <secondary_id>20121564</secondary_id>
    <nct_id>NCT01710332</nct_id>
  </id_info>
  <brief_title>The Safety &amp; Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy</brief_title>
  <acronym>CONTAIN</acronym>
  <official_title>Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A preliminary study to determine the safety and efficacy of intravitreal aflibercept
      injection in patients with persistent central serous chorioretinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A
      Prospective Pilot Study
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety of intravitreal aflibercept injection</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be measured by the amount, significance and details of adverse events/reactions to the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vision based on letter score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline in best-corrected ETDRS (Early Treatment of Diabetic Retinopathy Study) letter score
Percentage of eyes with 20/40 or better vision
Percentage of eyes with ≥ 15-letter gain from baseline
Percentage of eyes with &lt; 15-letter loss from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>Intravitreal Aflibercept Injection (x4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg / Intravitreal / every 1 month x 3 months and at month 4 (Drug administered 4 times).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal Aflibercept Injection (x6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg / Intravitreal / every 1 month x 6 months ((Drug administered 6 times).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Aflibercept Injection</intervention_name>
    <description>GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).
GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total).</description>
    <arm_group_label>Intravitreal Aflibercept Injection (x4)</arm_group_label>
    <arm_group_label>Intravitreal Aflibercept Injection (x6)</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-treatment acuity of 20/40- 20/320

          -  Macular fluid on optical coherence tomography for greater than 3 months

          -  Leakage on fluorescein angiography

          -  Willing and able to comply with clinic visits and study-related procedures

          -  Provide signed informed consent

        Exclusion Criteria:

          -  Treatment for CSCR in the study eye (anti-VEGF, PDT, or laser) within three months
             prior to study enrollment

          -  Presence of choroidal neovascularization on enrollment imaging

          -  Prior vitrectomy in the study eye

          -  Presence of any substantial ocular disease (other than CSCR) that may compromise
             vision in the study eye and /or confound interpretation of the data; e.g. substantial
             cataracts, advanced glaucoma, optic neuritis, optic neuropathy or atrophy, marked
             macular atrophy, ocular vascular occlusion, history of retinal detachment, uveitis,
             viral or other forms of chorioretinitis, etc.

          -  History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the
             study eye

          -  Uncontrolled glaucoma in the study eye (defined as IOP ≥ 25 mmHg despite treatment
             with anti-glaucoma medication)

          -  Active ocular infection or inflammation in the study eye

          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either
             eye

          -  Prior treatment with systemic anti-VEGF agents

          -  Cerebrovascular accident or myocardial infarction within the preceding 6 months.

          -  History of allergy to fluorescein, povidone iodine (Betadine) or aflibercept

          -  Participation in a study of an investigational drug or device within 30 days prior to
             potential enrollment into the study

          -  Pregnant or breast-feeding women Sexually active men* or women of childbearing
             potential** who are unwilling to practice adequate contraception during the study
             (adequate contraceptive measures include stable use of oral contraceptives or other
             prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to
             screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom
             plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge,
             foam, or jelly)

               -  Contraception is not required for men with documented vasectomy.

                    -  Postmenopausal women must be amenorrheic for at least 12 months in order
                       not to be considered of child bearing potential.  Pregnancy testing and
                       contraception are not required for women with documented hysterectomy or
                       tubal ligation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen Ho, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Mid Atlantic Retina- Huntingdon Valley</name>
      <address>
        <city>Huntingdon Valley</city>
        <state>Pennsylvania</state>
        <zip>19006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retna- Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 24, 2013</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Brian Burke, MPH</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>Persistent</keyword>
  <keyword>Central</keyword>
  <keyword>Serous</keyword>
  <keyword>Chorioretinopathy</keyword>
  <keyword>Regeneron</keyword>
  <keyword>CSR</keyword>
  <keyword>CSCR</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
